Comparison
Epitalon vs Omega-3 (EPA/DHA)
Side-by-side of Epitalon and Omega-3 (EPA/DHA). Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Epitalon
Epitalon peptide (Epithalon, tetrapeptide AEDG): telomerase activation, lifespan extension data, anti-aging trials, dosage, half-life, and safety.
Omega-3 (EPA/DHA)
Omega 3 fish oil profile: EPA/DHA marine fatty acids, 2-4 g/day cuts triglycerides 20-30%, REDUCE-IT showed 25% cardiovascular risk reduction on icosapent eth.
Effects at a glance
Epitalon
- •Synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed at the St. Petersburg Institute of Bioregulation
- •Russian clinical literature reports mortality reduction in elderly cohorts and improved melatonin output
- •Reported telomerase activation in human somatic cell culture and lifespan extension in mice and Drosophila
- •Independent Western replication is essentially absent; no FDA-standard RCTs
- •Anecdotal protocols use 5 to 10 mg subcutaneously daily for 10 to 20 day cycles, 2 to 4 times yearly
- •Not currently on the WADA Prohibited List
Omega-3 (EPA/DHA)
- •Reduces fasting triglycerides 20-50% at 2-4 g/day in hypertriglyceridemic patients
- •REDUCE-IT showed 25% relative risk reduction in major CV events at 4 g/day icosapent ethyl
- •Modest antidepressant effect (SMD ~0.40) for EPA-dominant formulations at 1-2 g/day
- •Atrial fibrillation incidence rises ~30-50% at 4 g/day; relevant for older patients with pre-existing CV disease
- •Tissue omega-3 index (RBC EPA + DHA) target ~8%; Western baseline typically 4-5%
- •Triglyceride and re-esterified triglyceride forms absorb ~70% better than ethyl esters in fasted state
Side-by-side
| Attribute | Epitalon | Omega-3 (EPA/DHA) |
|---|---|---|
| Category | peptide | supplement |
| Also known as | Epithalon, Ala-Glu-Asp-Gly, AEDG, Epithalamin (precursor extract) | fish oil, EPA, DHA, marine omega-3 |
| Half-life (hr) ↗ | 0.5 | 48 |
| Typical dose (mg) ↗ | 5 | 2000 |
| Dosing frequency | daily during cycle | 1 to 2 times daily with food |
| Routes | subcutaneous, intramuscular, intranasal | oral |
| Onset (hr) | 24 | 4 |
| Peak (hr) | 168 | 12 |
| Molecular weight | 390.35 | 302.45 |
| Molecular formula | C14H22N4O9 | C20H30O2 (EPA); C22H32O2 (DHA) |
| Mechanism | Synthetic tetrapeptide proposed to interact directly with DNA and chromatin to modulate tissue-specific gene expression. Reported effects include telomerase activation, increased melatonin output from pineal cells, and circadian normalization. | Substitutes arachidonic acid in membrane phospholipids, shifting eicosanoid production toward less-inflammatory 3-series prostaglandins and 5-series leukotrienes. Activates PPAR-alpha to lower hepatic VLDL/triglyceride synthesis. DHA modulates synaptic membrane fluidity and neuronal function. |
| Legal status | Not FDA approved; registered in Russia under domestic pharmaceutical framework; research-use-only grey market in US/EU | Dietary supplement; prescription forms (icosapent ethyl, omega-3 acid ethyl esters) for severe hypertriglyceridemia |
| WADA status | unknown | allowed |
| DEA / Rx | Not scheduled (research chemical) | Not scheduled |
| Pregnancy | Insufficient data; not recommended | Recommended at 200 to 600 mg DHA/day for fetal development |
| CAS | 307297-39-8 | 10417-94-4 |
| PubChem CID | 219042 | 446284 |
| Wikidata | Q5384126 | Q207688 |
Safety profile
Epitalon
Common side effects
- injection-site reactions
- occasional mild headache (rare)
Contraindications
- pregnancy
- lactation
- active malignancy (theoretical telomerase concern)
- concurrent immunosuppression
Interactions
- melatonin: potential additive effect on circadian and pineal output; no controlled data(minor)
Omega-3 (EPA/DHA)
Common side effects
- fishy aftertaste
- eructation (fish burps)
- mild dyspepsia
- loose stools at high doses
Contraindications
- fish allergy (use algal omega-3 alternative)
- active bleeding disorders
- scheduled surgery (discontinue 5-7 days prior)
Interactions
- warfarin and DOACs: additive antiplatelet effect at 2+ g/day; meaningful bleeding risk(moderate)
- aspirin and antiplatelet agents: additive bleeding risk at high doses(moderate)
- statins: complementary cardiovascular effects; no pharmacokinetic interaction(minor)
- antiarrhythmics: high-dose omega-3 increases AF risk; relevant in pre-existing arrhythmia(moderate)
Which Should You Take?
Omega-3 (EPA/DHA) comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Epitalon is the right call when one of the conditionals below applies.
- → If your priority is sleep onset or sleep quality, pick Epitalon.
- → If your priority is circadian regulation, pick Epitalon.
- → If your priority is cardiovascular health, pick Omega-3 (EPA/DHA).
- → If your priority is focus or working memory, pick Omega-3 (EPA/DHA).
Edge case: If you want to avoid research-only / gray-market sourcing, Omega-3 (EPA/DHA) is the more accessible choice.
Default choice: Omega-3 (EPA/DHA). Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Epitalon only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Epitalon and Omega-3 (EPA/DHA)?
Epitalon and Omega-3 (EPA/DHA) differ in category (peptide vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Epitalon or Omega-3 (EPA/DHA)?
Epitalon half-life is 0.5 hours; Omega-3 (EPA/DHA) half-life is 48 hours.
Can you stack Epitalon with Omega-3 (EPA/DHA)?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper